HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $26
REGENXBIO, Inc.
REGENXBIO, Inc. RGNX | 0.00 |
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:
RGNX) with a Buy and lowers the price target from $30 to $26.
